2 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Rallybio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants RLYB116 for Injection - Hematologic Diseases, Autoimmune Diseases | Phase 1 | Completed | Rallybio | 16 | 2025-04-14 | 2026-02-27 |
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization Anti-(integrin beta-3) human monoclonal antibody - Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 2 | Terminated | Rallybio | 1 | 2024-11-21 | 2026-03-06 |
| Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia Clinical data collection - Fetal and Neonatal Alloimmune Thrombocytopenia | Completed | Rallybio | 14390 | 2022-03-14 | 2026-03-06 |
Thrombocytopenia, Neonatal Alloimmune (2) · Autoimmune Diseases (1) · Hematologic Diseases (1)
Injections (1)
Netherlands (2) · Norway (2) · Sweden (2) · Australia (1) · Canada (1) · Germany (1) · United Kingdom (1) · United States (1)